In order to test the safety and efficacy of SmithKline Beecham Biologicals' herpes simplex vaccine (gD-Alum-MPL), a double-blind, randomized, placebo controlled study will be conducted in healthy adult volunteers with or without positive serological markers of herpes simplex infection (HSV1 and/or 2) but without genital herpes disease. The vaccinations will be given at 0, 1 and 6 months. Safety and humoral immune response follow-up visits will extend until Month 19. Since herpes simplex infections are extremely common, determination of the safety and efficacy of an HSV vaccine has immense prophylactic and therapeutic indications.
Showing the most recent 10 out of 465 publications